These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 7615839)

  • 21. Lipid-free apolipoprotein (apo) A-I is converted into alpha-migrating high density lipoproteins by lipoprotein-depleted plasma of normolipidemic donors and apo A-I-deficient patients but not of Tangier disease patients.
    von Eckardstein A; Huang Y; Kastelein JJ; Geisel J; Real JT; Kuivenhoven JA; Miccoli R; Noseda G; Assmann G
    Atherosclerosis; 1998 May; 138(1):25-34. PubMed ID: 9678768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of high-density lipoprotein particles containing apo A-I, with or without apo A-II, on intracellular cholesterol efflux.
    Oikawa S; Mendez AJ; Oram JF; Bierman EL; Cheung MC
    Biochim Biophys Acta; 1993 Jan; 1165(3):327-34. PubMed ID: 8418891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tangier disease: epidemiology, pathophysiology, and management.
    Puntoni M; Sbrana F; Bigazzi F; Sampietro T
    Am J Cardiovasc Drugs; 2012 Oct; 12(5):303-11. PubMed ID: 22913675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective inhibition of free apolipoprotein-mediated cellular lipid efflux by probucol.
    Tsujita M; Yokoyama S
    Biochemistry; 1996 Oct; 35(40):13011-20. PubMed ID: 8855936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cellular cholesterol efflux in heterozygotes for tangier disease is markedly reduced and correlates with high density lipoprotein cholesterol concentration and particle size.
    Brousseau ME; Eberhart GP; Dupuis J; Asztalos BF; Goldkamp AL; Schaefer EJ; Freeman MW
    J Lipid Res; 2000 Jul; 41(7):1125-35. PubMed ID: 10884295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apolipoproteins.
    Wolfbauer G; Albers JJ; Oram JF
    Biochim Biophys Acta; 1999 Jul; 1439(1):65-76. PubMed ID: 10395966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular cholesterol efflux is modulated by phospholipid-derived signaling molecules in familial HDL deficiency/Tangier disease fibroblasts.
    Haidar B; Mott S; Boucher B; Lee CY; Marcil M; Genest J
    J Lipid Res; 2001 Feb; 42(2):249-57. PubMed ID: 11181755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective down-regulation by protein kinase C inhibitors of apolipoprotein-mediated cellular cholesterol efflux in macrophages.
    Li Q; Tsujita M; Yokoyama S
    Biochemistry; 1997 Oct; 36(40):12045-52. PubMed ID: 9315842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is the decreased high-density lipoprotein cholesterol in the metabolic syndrome due to cellular lipid efflux defect?
    Alenezi MY; Marcil M; Blank D; Sherman M; Genest J
    J Clin Endocrinol Metab; 2004 Feb; 89(2):761-4. PubMed ID: 14764793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of Tangier lipoproteins with cholesteryl ester-laden mouse peritoneal macrophages.
    Schmitz G; Assmann G; Brennhausen B; Schaefer HJ
    J Lipid Res; 1987 Jan; 28(1):87-99. PubMed ID: 3559403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transfer of lipids to high-density lipoprotein (HDL) is altered in patients with familial hypercholesterolemia.
    Martinez LR; Santos RD; Miname MH; Deus DF; Lima ES; Maranhão RC
    Metabolism; 2013 Aug; 62(8):1061-4. PubMed ID: 23540443
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accumulation of cardiolipin and lysocardiolipin in fibroblasts from Tangier disease subjects.
    Fobker M; Voss R; Reinecke H; Crone C; Assmann G; Walter M
    FEBS Lett; 2001 Jul; 500(3):157-62. PubMed ID: 11445077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholesterol efflux from normal and Tangier disease fibroblasts into normal, high-density lipoprotein-deficient, and apolipoprotein E-deficient plasmas.
    Schuler-Lüttmann S; Zhu Y; Hoffmann M; März W; Feussner G; Wieland H; Assmann G; von Eckardstein A
    Metabolism; 2000 Jun; 49(6):770-7. PubMed ID: 10877205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids.
    Oram JF; Yokoyama S
    J Lipid Res; 1996 Dec; 37(12):2473-91. PubMed ID: 9017501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apolipoprotein AI efficiently binds to and mediates cholesterol and phospholipid efflux from human but not rat aortic smooth muscle cells.
    Francis GA; Tsujita M; Terry TL
    Biochemistry; 1999 Dec; 38(49):16315-22. PubMed ID: 10587456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The metabolic fate of apolipoprotein A-I-containing lipoproteins internalized into HepG2 cells: resecreted lipoproteins as a potent inducer for cholesterol efflux.
    Sasahara T; Kobori S; Kasho M; Sato Y; Nishikawa T; Yano T; Takeda H; Shichiri M
    Atherosclerosis; 1994 Apr; 106(2):179-90. PubMed ID: 8060378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell lipid metabolism modulators 2-bromopalmitate, D609, monensin, U18666A and probucol shift discoidal HDL formation to the smaller-sized particles: implications for the mechanism of HDL assembly.
    Quach D; Vitali C; La FM; Xiao AX; Millar JS; Tang C; Rader DJ; Phillips MC; Lyssenko NN
    Biochim Biophys Acta; 2016 Dec; 1861(12 Pt A):1968-1979. PubMed ID: 27671775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apolipoprotein AI and HDL(3) inhibit spreading of primary human monocytes through a mechanism that involves cholesterol depletion and regulation of CDC42.
    Diederich W; Orsó E; Drobnik W; Schmitz G
    Atherosclerosis; 2001 Dec; 159(2):313-24. PubMed ID: 11730811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Normal HDL-apo AI turnover and cholesterol enrichment of HDL subclasses in New Zealand rabbits with partial nephrectomy.
    Toledo-Ibelles P; Franco M; Carreón-Torres E; Luc G; Tailleux A; Vargas-Alarcón G; Fragoso JM; Aguilar-Salinas C; Luna-Luna M; Pérez-Méndez O
    Metabolism; 2013 Apr; 62(4):492-8. PubMed ID: 23089050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical studies in a patient with a Tangier syndrome.
    Yao JK; Herbert PN; Fredrickson DS; Ellefson RD; Heinen RJ; Forte T; Dyck PJ
    J Neuropathol Exp Neurol; 1978; 37(2):138-54. PubMed ID: 632844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.